Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Vaccine|January 9, 2023
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)Robert Lupinacci, Richard Rupp, Orasri Wittawatmongkol, et al.
Vaccine|December 15, 2022
A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)Androniki Bili, Scott Dobson, Jeffrey Quinones, et al.
Blood Advances|November 16, 2022
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) studyCharles T Quinn, Richard T Wiedmann, Daniel Jarovsky, et al.
AIDS (London, England)|November 9, 2021
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIVLerato Mohapi, Yvett Pinedo, Olayemi Osiyemi, et al.
Vaccines|January 28, 2026
Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health SitesLaura L Hammitt, Ulrike K Buchwald, Jennifer McCauley, et al.
The Lancet. Infectious Diseases|September 18, 2022
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trialHeather Platt, Tosin Omole, Jose Cardona, et al.
Vaccine|September 7, 2021
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)Joon-Young Song, Chih-Jen Chang, Charles Andrews, et al.
Pediatrics|June 13, 2023
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 StudyNatalie Banniettis, Michael Horn, Manish Sadarangani, et al.
Human Vaccines & Immunotherapeutics|March 3, 2023
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factorsLaura L Hammitt, Dean Quinn, Ewa Janczewska, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2023
A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)Marissa Wilck, Oliver A Cornely, Catherine Cordonnier, et al.
Pageof 2